Trillium Therapeutics Inc
TRIL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.01M
Close$
$2.11
89.4% downside
Current Fair Value
89.4% downsideOvervalued by 89.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.01 Million |
|---|---|
| Enterprise Value | $-91,566,522.00 |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 2.21 |
| Outstanding Shares | - |
Return
| Return on Equity | 26.76% |
|---|---|
| Return on Assets | 24.53% |
| Return on Invested Capital | 26.83% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -2129.45 |
| Enterprise Value to EBIT | -1.4 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Trillium Therapeutics Inc
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.